GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?

Name: GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?
Start: 2021-05-27T00:00:00Z
End: 2021-05-27T00:00:00Z

May 27, 2021

Webinar

LSPN Connect

Finnegan partner Cora Holt will discuss the potential impact the GSK v Teva case will have on both brand and generic drug manufacturers. For more information, or to register, please see LSPN Connect’s website.

Related Insights

Conference

IAM Live: Navigating the UPC 2026

November 3, 2026

Paris

Conference

2026 EDTX Bench Bar Conference

October 28-30, 2026

Fort Worth

Seminar

Future IP UK

October 21, 2026

London

Webinar

Successful Strategies to Win Alice Motions and Fee Awards in Patent Cases Against Non-Practicing Entities

July 22, 2026

Webinar

Early Motions in Trade Secret Litigation – Offensive and Defensive Insights

July 15, 2026

Webinar

Articles

When the Classroom Goes Dark: Lessons from the Canvas Breach for Corporate Cyber Preparedness

July 8, 2026

Webinar

Inventive Step in Europe and the US: Comparing the UPC, EPO and National Approaches

July 8, 2026

Webinar

Federal Circuit IP Blog

Federal Circuit Vacates and Remands Infringement and Damages Judgment After Erroneous Verdict Form and Eligibility Analysis

July 8, 2026

Federal Circuit IP Blog

“2” Does Not Provide Written Description Support for “1”: Federal Circuit Affirms District Court’s Invalidation of Patent

July 8, 2026

GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?

Tags

Related Practices

Related Industries

Related Professionals

Related Insights